GRITTI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 601
EU - Europa 333
AS - Asia 162
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.103
Nazione #
US - Stati Uniti d'America 591
IT - Italia 103
IE - Irlanda 61
SG - Singapore 60
SE - Svezia 49
HK - Hong Kong 44
DE - Germania 38
RU - Federazione Russa 30
CN - Cina 25
ID - Indonesia 18
UA - Ucraina 15
CA - Canada 10
GB - Regno Unito 8
VN - Vietnam 6
BR - Brasile 4
FI - Finlandia 4
BE - Belgio 3
FR - Francia 3
IN - India 3
NL - Olanda 3
PT - Portogallo 3
TR - Turchia 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
NO - Norvegia 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
AU - Australia 1
ES - Italia 1
HU - Ungheria 1
JP - Giappone 1
KR - Corea 1
PE - Perù 1
PK - Pakistan 1
RO - Romania 1
SI - Slovenia 1
Totale 1.103
Città #
Ann Arbor 97
Chandler 62
Dublin 58
Singapore 50
Hong Kong 44
Woodbridge 42
Fairfield 38
Frankfurt am Main 33
Santa Clara 28
Ashburn 27
Wilmington 26
New York 22
Jakarta 18
Princeton 18
Seattle 18
Houston 17
Lissone 16
Absecon 14
Jacksonville 14
Cambridge 13
Milan 12
Shanghai 10
Dearborn 9
Lawrence 8
Toronto 7
Altamura 6
London 6
San Diego 6
Andover 5
Arezzo 5
Dong Ket 5
Fremont 5
Cagliari 4
Brussels 3
Florence 3
Los Angeles 3
Mountain View 3
Redmond 3
Rome 3
Turin 3
Amsterdam 2
Azzano San Paolo 2
Brescia 2
Brno 2
Carate 2
Carate Brianza 2
Genova 2
Kocaeli 2
Lachine 2
Lisbon 2
Melzo 2
Nanchang 2
Nanjing 2
New Haven 2
Oslo 2
Vila Velha 2
Athens 1
Bari 1
Baschi 1
Brugherio 1
Budapest 1
Changchun 1
Clifton 1
Cologno Monzese 1
Curitiba 1
Dallas 1
Denkendorf 1
Durham 1
Hangzhou 1
Hebei 1
Helsinki 1
Kenthurst 1
Lima region 1
Ljubljana 1
Madrid 1
Magdeburg 1
Montréal 1
Munich 1
Norwalk 1
Nuremberg 1
Osaka 1
Parma 1
Qingdao 1
San Francisco 1
Santeramo In Colle 1
Shenyang 1
St-Legier-La Chiesaz 1
Suri 1
Varese 1
Washington 1
Yueqing 1
Totale 831
Nome #
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 240
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: A GIMEMA Multicenter Phase II Trial 170
Development of new therapeutic strategies in mature T-cell non-Hodgkin lymphomas 162
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia 155
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 83
Skip pattern approach toward the early access of innovative anticancer drugs 80
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 78
Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab 52
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 37
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 26
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma 10
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C 9
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study 7
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma 6
SAKK38/07 study: Integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model 6
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma 6
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study 6
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 6
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study 5
High inter-follicular spatial co-localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma 5
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma 5
Spleen tyrosine kinase/FMS-Like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/ CB-659 5
Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma 4
Genetic and phenotypic attributes of splenic marginal zone lymphoma 4
Chimeric antigen receptor T cells for gamma–delta T cell malignancies 4
Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure 4
DeepMIF: Deep Learning Based Cell Profiling for Multispectral Immunofluorescence Images with Graphical User Interface 4
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 4
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy 4
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences 4
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 4
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up 4
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia 4
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL 4
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis 4
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- And T-cell lymphoma models 4
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma 4
Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell–redirected bispecific antibodies 4
Totale 1.223
Categoria #
all - tutte 5.546
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.546


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202026 0 0 0 0 0 0 7 5 8 2 3 1
2020/2021176 4 25 21 19 12 19 8 15 13 21 5 14
2021/2022144 9 9 11 11 15 11 6 17 3 11 15 26
2022/2023209 25 53 25 15 12 34 8 10 20 1 3 3
2023/2024167 7 2 6 13 20 34 34 6 14 6 4 21
2024/2025313 15 42 26 19 34 121 56 0 0 0 0 0
Totale 1.223